Description
The abstract mentions BACE2 as homologous to BACE1 but provides no functional characterization. Understanding BACE2’s role is important for selective therapeutic targeting and understanding the complete biology of this protease family.
Gap type: open_question Source paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:47.880307+00:00”, “resolution_summary”: “Resolved by hypothesis h-73124693: BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imbalance via PV Interneuron Hypofunction. Supporting evidence includes debate sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-73124693”, “title”: “BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imbalance via PV Interneuron Hypofunction”, “score”: 0.229, “reason”: “19 token overlaps; entity overlap: bace1”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “target_gene”: “NRG1/ERBB4”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.743, “confidence_score”: 0.72, “status”: “promoted”, “pubmed_evidence_ids”: [“16990514”, “17099708”, “20393464”, “20943921”, “21209185”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.702, “reason”: “14 token overlaps; entity overlap: bace1, pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062132-e71b3ef7_task_73907230”, “title”: “The abstract mentions multiple organelles synchronously present structural derangement in diseases like neurodegeneration, but doesn’t explain how mitophagy, reticulophagy, and other selective autophagy processes coordinate. Understanding this coordination is critical for therapeutic targeting.\n\nGap type: unexplained_observation\nSource paper: Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles. (2021, Autophagy, PMID:32048886)”, “score”: 0.444, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062132-e71b3ef7”, “quality_score”: 0.8, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974_20260412-213444”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.433, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.7, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974_20260416-134419”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.433, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2_task_9aae8fc5”, “title”: “While the abstract identifies AQP4 as a ‘potential and promising target’ and mentions it could provide ‘new therapeutic alternatives,’ the specific approaches for therapeutic modulation of AQP4 function are not defined. This represents a critical translational gap for moving from mechanistic understanding to clinical intervention.\n\nGap type: open_question\nSource paper: Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. (2023, Neurobiol Dis, PMID:36796590)”, “score”: 0.423, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}